Purinergic control of neuropathic pain

Drug Development Research

Volumn 67, Issue 4, 2006, Pages 376-388

  McGaraughty, Steve ^a   Jarvis, Michael F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ATP; Neuropathic pain; Purinergic receptors

Indexed keywords

A 317491; ADENOSINE; ADENOSINE TRIPHOSPHATE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CELL SURFACE RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR A1; G PROTEIN COUPLED RECEPTOR A2A; G PROTEIN COUPLED RECEPTOR A2B; G PROTEIN COUPLED RECEPTOR A3; GUANINE NUCLEOTIDE BINDING PROTEIN; METABOTROPIC RECEPTOR; PICRIC ACID; PURINE ANTAGONIST; PURINE P2X RECEPTOR; PURINE P2X2 RECEPTOR; PURINE P2X3 RECEPTOR; PURINE P2X4 RECEPTOR; PURINE P2X7 RECEPTOR; PURINE P2Y RECEPTOR; PURINE P2Y2 RECEPTOR; PURINE P2Y4 RECEPTOR; PURINE P2Y6 RECEPTOR; PURINE RECEPTOR; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; RECEPTOR SUBTYPE; SURAMIN; UNCLASSIFIED DRUG;

CHRONIC PAIN; CLINICAL TRIAL; HUMAN; NERVE EXCITABILITY; NEUROMODULATION; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PERIPHERAL NERVE; REVIEW; SENSITIZATION; SENSORY NERVE CELL; SPINAL CORD; UNSPECIFIED SIDE EFFECT;

EID: 33747780797     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20101     Document Type: Review

References (176)

1. Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, King BF, Cachet C, Jacobson KA, Weisman GA, Burnstock G. 2003. Characterization of the UDP-glucose receptor (re-named here the P2Y(14) receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 24:52-55.
2. Arch JRS, Newsholme EA. 1978. Activities and some properties of 5′-nucleotidase, adenosine kinase and adenosine deaminase in tissues from vertebrates and invertebrates in relation to the control of the concentration and the physiological role of adenosine. Biochem J 174:965-977.
3. Bantel C, Childers SR, Eisenach JC. 2002a. Role of adenosine receptors in spinal G-protein activation after peripheral nerve injury. Anesthesiology 96:1443-1449.
4. Bantel C, Tobin JR, Li X, Childers SR, Chen SR, Eisenach JC. 2002b. Intrathecal adenosine following spinal nerve ligation in rat: short residence time in cerebrospinal fluid and no change in A(1) receptor binding. Anesthesiology 96:103-108.
5. Barclay J, Patel S, Dorn G, Wotherspoon G, Moffatt S, Eunson L, Abdel'al S, Natt F, Hall J, Winter J, Bevan S, Wishart W, Fox A, Ganju P. 2002. Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain. J Neurosci 22:8139-8147.
6. Barden JA, Bennett MR. 2000. Distribution of P2X purinoceptor clusters on individual rat dorsal root ganglion cells. Neurosci Lett 287:183-186.
7. Belfrage M, Sollevi A, Segerdahl M, Sjolund KF, Hansson P. 1995. Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Anesth Analg 81:713-717.
8. Bennett AD, Everhart AW, Hulsebosch CE. 2003. Direct evidence of primary afferent sprouting in distant segments following spinal cord injury in the rat: colocalization of GAP-43 and CGRP. Exp Neurol 184:373-380.
9. Bian D, Nichols ML, Ossipov MH, Lai J, Porreca F. 1995. Characterization of the anti-allodynic efficacy of morphine in a model of neuropathic pain in rats. Neuroreport 6:1981-1984.
10. Bianchi BR, Lynch KJ, Touma E, Niforatos W, Burgard EC, Alexander KM, Park HS, Yu H, Metzger R, Kowaluk EA, Jarvis MF, van Biesen T, 1999. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol 376:127-138.
11. Bland-Ward PA, Humphrey PPA. 1997. Acute nociception mediated by hindpaw P2X receptor activation in the rat. Br J Pharmacol 122:366-371.
12. Bonizzoni E, Milani S, Ongini E, Casati C, Monopoli A. 1995. Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a ADO Agonists. Hypertension 25:564-569.
13. Bradbury EJ, Burnstock G, McMahon SB. 1998. The expression of P2X3 purinoceptors in sensory neurons: effects of axotomy and glial-derived neurotrophic factor. Mol Cell Neurosci 12:256-268.
14. Britton DR, Mikusa, J, Lee C-H, Jarvis MF, Williams M, Kowaluk EA. 1999. Site and event specific increase of striatal adenosine release by adenosine kinase inhibition in rats. Neurosci Lett 266:93-96.
15. Brundege JM, Dunwiddie TV. 1997. Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv Pharmacol 39:353-391.
16. Buell G, Lewis C, Collo G, North RA, Surprenant A. 1996. An antagonist-insensitive P2X receptor expressed in epithelia and brain. EMBO J 15:55-62.
17. Burgard EC, Niforatos W, van Biesen T, Lynch KJ, Touma E, Metzger RE, Kowaluk EA, Jarvis MF. 1999. P2X receptor-mediated ionic currents in dorsal root ganglion neurons. J Neurophysiol 82:1590-1598.
18. Burnstock G. 1972. Purinergic nerves. Pharmacol Rev 24:509-581.
19. Burnstock G. 1996. A unifying purinergic hypothesis for the initiation of pain. Lancet 347:1604-1605.
20. Burnstock G. 2000. P2X receptors on sensory neurons. Br J Anaesth 84:476-488.
21. Burnstock G, Wood JN. 1996. Purinergic receptors: their role in nociception and primary afferent neurotransmission. Curr Opin Neurobiol 6:526-532.
22. Chen C-C, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN. 1995. A P2X purinoceptor expressed by a subset of sensory neurons. Nature (Lond) 377:428-431.
23. Chen Y, Shu Y, Zhao Z. 1999. Ectopic purinergic sensitivity develops at sites of chronic nerve constriction injury in rat. NeuroReport 10:2779-2782.
24. Chen Y, Zhang Y-H, Zhao Z-Q. 2001. Novel purinergic sensitivity develops in injured sensory axons following sciatic nerve transection in rat. Brain Res 911:168-172.
25. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN. 2005. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114:386-396.
26. Chiari AI, Eisenach JC. 1999. Intrathecal adenosine: interactions with spinal clonidine and neostigmine in rat models of acute nociception and postoperative hypersensitivity. Anesthesiology 90:1413-1421.
27. Chiari A, Yaksh TL, Myers RR, Provencher J, Moore L, Lee CS, Eisenach JC. 1999. Preclinical toxicity screening of intrathecal adenosine in rats and dogs. Anesthesiology 91:824-832.
28. Chizh BA, Dusch M, Puthawala M, Schmelz M, Cookson LM, Martina R, Brown J, Koppert W 2004. The effect of intravenous infusion of adenosine on electrically evoked hyperalgesia in a healthy volunteer model of central sensitization. Anesth Analg 99:816-822.
29. 2 adenosine receptors in the rat spinal cord. J Pharmacol Exp Ther 242:905-910.
30. Choca JI, Green RD, Proudfit HK. 1988. Adenosine A1 and A2 receptors of the substantia gelatinosa are located predominantly on intrinsic neurons: an autoradiography study. J Pharmacol Exp Ther 247:757-764.
31. Cockayne DA, Hamilton SG, Zhu Q-M, Dunn PM, Zhong Y, Novakovic S, Malmberg AB, Cain G, Berson A, Kassotakis L, Hedley L, Lachnit WG, Burnstock G, McMahon SB, Ford APDW. 2000. Urinary bladder hyporeflexia and reduced pain-related behavior in P2X3-deficient mice. Nature (Lond) 407:1011-1015.
32. 6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. J Neurosci 16:2495-2507.
33. Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G. 1997. Tissue distribution of the P2X7 receptor. Neuropharmacology 36:1277-1283.
34. Cook SP, McCleskey EW. 2002. Cell damage excites nociceptors through release of cytosolic ATP. Pain 95:41-47.
35. Cook SP, Vulchanova L, Hargreaves KM, Elde R, McCleskey EW 1997. Distinct ATP receptors on pain-sensing and stretch-sensing neurons. Nature (Lond) 387:505-508.
36. Coyle DE. 1998. Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia 23:75-83.
37. 2 adenosine receptors in spinal mechanisms of antinociception. Eur J Pharmacol 139:215-223.
38. DeLeo JA, Yezierski RP. 2001. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90:1-6.
39. Deuchars SA, Atkinson L, Brooke RE, Musa H, Milligan CJ, Batten TF, Buckley NJ, Parson SH, Deuchars J. 2001. Neuronal P2X7 receptors are targeted to presynaptic terminals in the central and peripheral nervous systems. J Neurosci 21:7143-7152.
40. De Vry J, Kuhl E, Franken-Kunkel P, Eckel G. 2004. Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol 491:137-148.
41. Di Virgilio F, Borea PA, Illes P. 2001. P2 receptors meet the immune system. Trends Pharmacol Sci 22:5-7.
42. Driessen B, Reimann W, Selve N, Friderichs E, Bultmann R. 1994. Antinociceptive effect of intrathecally administered P2-purinoceptor antagonists in rats. Brain Res 666:182-188.
43. Dunwiddie TV, Masino SA. 2001. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24:31-55.
44. Eisenach JC, Curry R, Hood DD. 2002a. Dose response of intrathecal adenosine in experimental pain and allodynia. Anesthesiology 97:938-942.
45. Eisenach JC, Hood DD, Curry R. 2002b. Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology 96:29-34.
46. Eisenach JC, Rauck RL, Curry R. 2003. Intrathecal, but not intravenous adenosine reduces allodynia in patients with neuropathic pain. Pain 105:65-70.
47. Eisenach JC, Zhang Y, Duflo F. 2005. alpha2-adrenoceptors inhibit the intracellular Ca2+ response to electrical stimulation in normal and injured sensory neurons, with increased inhibition of calcitonin gene-related peptide expressing neurons after injury. Neuroscience 131:189-197.
48. Engler R. 1987. Consequences of activation and adenosine mediated inhibition of granulocytes during myocardial ischemia. Fed Proc 46:2407-2412.
49. Esquisatto LC, Costa SK, Camargo EA, Ribela MT, Brain SD, de Nucci G, Antunes E. 2001. The plasma protein extravasation induced by adenosine and its analogues in the rat dorsal skin: evidence for the involvement of capsaicin sensitive primary afferent neurones and mast cells. Br J Pharmacol 134:108-115.
50. Esser MJ, Sawynok J. 2000. Caffeine blockade of the thermal anti-hyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. Eur J Pharmacol 399:131-139.
51. Esser MJ, Chase T, Allen GV, Sawynok J. 2001. Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions. Eur J Pharmacol 430:211-218.
52. Feoktistov I, Biaggioni I. 1997. Adenosine A2B receptors. Pharmacol Rev 49:381-402.
53. Fredholm BB. 1997. Adenosine and neuroprotection. Int Rev Neurobiol 40:259-280.
54. Fukuhara N, Imai Y, Sakakibara A, Monta K, Kitayama S, Tanne K, Dohl T. 2000. Regulation of the development of allodynia by intrathecally administered P2 purinoceptor agonists and antagonists in mice. Neurosci Lett 292:25-28.
55. Fukui M, Takishita A, Zhang N, Nakagawa T, Minami M, Satoh M. 2004. Involvement of locus coeruleus noradrenergic neurons in supraspinal antinociception by alpha,beta-methylene-ATP in rats. J Pharmacol Sci 94:153-160.
56. Gardell LR, Vanderah TW, Gardell SE, Wang R, Ossipov MH, Lai J, Porreca F 2003. Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J Neurosci 23:8370-8379.
57. Gerevich Z, Borvendeg SJ, Schroder W, Franke H, Wirkner K, Norenberg W, Furst S, Gillen C, Illes P. 2004. Inhibition of N-type voltage-activated calcium channels in rat dorsal root ganglion neurons by P2Y receptors is a possible mechanism of ADP-induced analgesia. J Neurosci 24:797-807.
58. Geiger JD, Naggy JI. 1984. Heterogeneous distribution of adenosine transport sites labeled by [3 H]nitrobenzylthioinosine in rat brain: an autoradiographic and membrane binding study. Brain Res 345:657-666.
59. 3H] Nitrobenzylthioinosine binding sites in rat spinal cord and primary afferent neurons. Brain Res 347:321-327.
60. Golembiowska K, White TD, Sawynok J. 1996. Adenosine kinase inhibitors augment release of adenosine from spinal cord slices. Eur J Pharmacol 307:157-162.
61. Gomes JA, Li X, Pan HL, Eisenach JC. 1999. Intrathecal adenosine interacts with a spinal noradrenergic system to produce antinociception in nerve-injured rats. Anesthesiology 91:1072-1079.
62. Gouder N, Fritschy JM, Boison D. 2003. Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 44:877-885.
63. Gu JG, MacDermott AB. 1997. Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses. Nature (Lond) 389:749-753.
64. Guieu R, Peragut JC, Roussel P, Hassani H, Sampieri F, Bechis G, Gola R, Rochat H. 1996. Adenosine and neuropathic pain. Pain 68:271-274.
65. Gyllenhammar E, Norfors L-O. 2001. Systemic adenosine infusions alleviated neuropathic pain. Pain 94:121-122.
66. Han HC, Lee DH, Chung JM. 2000. Characteristics of ectopic discharges in a rat neuropathic pain model. Pain 84:253-261.
67. Hanisch UK. 2002. Microglia as a source and target of cytokines. Glia 40:140-155.
68. Harden TK, Lazarowski ER. 1999. Release of ATP and UTP from astrocytoma cells. Prog Brain Res 120:135-143.
69. Hasko G, Cronstein BN. 2004. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25:33-39.
70. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C. 1998. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol 358:261-268.
71. Hayashida M, Fukuda K, Fukunaga A, Meno A, Sato K, Tarui K, Arita H, Kaneko Y, Hanaoka K. 2005. Analgesic effect of intravenous ATP on postherpetic neuralgia in comparison with responses to intravenous ketamine and lidocaine. J Anesth 19:31-35.
72. Ho BT, Huo YY, Lu JG, Newman RA, Levin VA. 1992. Analgesic activity of anticancer agent suramin. Anti-Cancer Drugs 3:91-94.
73. Holton FA, Holton PJ. 1954. The capillary dilator substances in dry powders of spinal roots; a possible role for adenosine triphosphate in chemical transmission from nerve endings. J Physiol 126:124-140.
74. Honore P, Kage K, Mikusa J, Watt AT, Johnston JF, Wyatt JR, Faltynek CR, Jarvis MF, Lynch K. 2002. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 99:11-19.
75. Houlton P. 1959. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J Physiol 145:494-504.
76. Huber JD, Witt KA, Hom S, Egleton RD, Mark KS, Davis TP 2001. Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 280:H1241-H1248.
77. Inoue K, Koizumi S, Tsuda M, Shigemoto-Mogami Y. 2003. Signaling of ATP receptors in glia-neuron interaction and pain. Life Sci 74:189-197.
78. Jacobson KA, Jarvis MF, Williams M. 2002. Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 45:4057-4093.
79. Jahr CE, Jessell TM. 1983. ATP excites a subpopulation of rat dorsal horn neurones. Nature (Lond) 304:730-733.
80. Jarvis MF, Yu H, Kohlhaas K, Alexander K, Lee C-H, Jiang M, Bhagwat SS, Williams M and Kowaluk EA. 2000. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6- morphorino-pyridin-3-yl)pyrido [2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor analgesic with anti-inflammatory properties. I. In vitro characterization. J Pharmacol Exp Ther 295:1156-1164.
81. Jarvis MF, Burgard EC, McGaraughty S, Honore P, Lynch K, Brennan TJ, Subieta A, Van Biesen T, Cartmell J, Bianchi B, Niforatos W, Kage K, Yu H, Mikusa J, Wismer CT, Zhu CZ, Chu K, Lee CH, Stewart AO, Polakowski J, Cox BF, Kowaluk E, Williams M, Sullivan J, Faltynek C. 2002a. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci USA 99:17179-17184.
82. Jarvis MF, Wismer CT, Schweitzer E, Yu H, van Biesen T, Lynch KJ, Burgard EC, Kowaluk E. 2001. Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X(3) allosteric modulator, cibacron blue. Br J Pharmacol 132:259-269.
83. Jarvis MF, Yu H, McGaraughty S, Wismer CT, Mikusa J, Zhu C, Chu K, Kohlhaas K, Cowart M, Lee C-H, Stewart AO, Cox BF, Polakowski J, Kowaluk EA. 2002b. Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor. Pain 96:107-118.
84. 3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology 34:393-403.
85. Kaelin-Lang A, Lauterburg T, Burgunder JM. 1998. Expression of adenosine A2a receptor gene in rat dorsal root and autonomic ganglia. Neurosci Lett 246:21-24.
86. Kage K, Niforatos W, Zhu CZ, Lynch KJ, Honore P, Jarvis MF. 2002. Alteration of dorsal root ganglion P2X3 receptor expression and function following spinal nerve ligation in the rat. Exp Brain Res 147:511-519.
87. Karlsten R, Cordh T Jr. 1995. An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth Analg 80:844-847.
88. Keil GJ, DeLander GE. 1994. Adenosine kinase and adenosine deaminase inhibition modulate spinal adenosine-and opioid agonist-induced antinociception in mice. Eur J Pharmacol 271:37-46.
89. Kim C, Chung JM, Chung K. 2003. Changes in the gene expression of six subtypes of P2X receptors in rat dorsal root ganglion after spinal nerve ligation. Neurosci Lett 337:81-84.
90. Kowaluk E, Mikusa J, Zhu C, Wismer C, Schweitzer E, Lynch J, Lee C-H, Jiang M, Bhagwat S, McKie J, Cox B, Polakowski J, Williams M, Jarvis MF. 2000. ABT-702, (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyriclin-3-yl)pyrido[2,3-d] pyridine), A novel orally effective adenosine kinase (AK) inhibitor with analgesic and anti-inflammatory properties: II Antinociceptive and antiinflaminatory effects in rat models of persistent, inflammatory, and neuropathic pain. J Pharmacol Exp Ther 295:1165-1174.
91. Kreutzberg GW. 1996. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312-318.
92. Kukley M, Stausberg P, Adelmann G, Chessell IP, Dietrich D. 2004. Ecto-nucleotidases and nucleoside transporters mediate activation of adenosine receptors on hippocampal mossy fibers by P2X7 receptor agonist 2′-3′-O-(4-benzoylbenzoyl)-ATP. J Neurosci 24:7128-7139.
93. Lavand'homme PM, Eisenach JC. 1999. Exogenous and endogenous adenosine enhance the spinal anti-allodynic effects of morphine in a rat model of neuropathic pain. Pain 80:31-36.
94. Le KT, Villeneuve P, Ramjaun AR, McPherson PS, Beaudet A, Seguela P. 1998. Sensory presynaptic and widespread somatodendritic immunolocalization of central ionotropic P2X ATP receptors. Neuroscience 83:177-190.
95. Lee YL, Yaksh TL. 1996. Pharmacology of the spinal adenosine receptor which mediates the anti-allodynic action of intrathecal adenosine agonists. J Pharmacol Exp Ther 277:1642-1648.
96. Lee YW, Chaplan SR, Yaksh TL. 1995. Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neurosci Lett 199:111-114.
97. Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, Watkins LR. 2005. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115:71-83.
98. Ledent C, Vauseois TM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M. 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388:674-678.
99. Li E, Perl E. 1994. Adenosine inhibition of synaptic transmission in the substantia gelatinosa. J Neurophysiol 4:1611-1621.
100. Li X, Bantel C, Conklin D, Childers SR, Eisenach JC. 2004. Repeated dosing with oral allosteric modulator of adenosine A1 receptor produces tolerance in rats with neuropathic pain. Anesthesiology 100:956-961.
101. Li X, Conklin D, Ma W, Zhu X, Eisenach JC. 2002. Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain. Pain 97:117-125.
102. Liu T, Tracey DJ. 2000. ATP P2X receptors play little role in the maintenance of neuropathic hyperalgesia. Neuroreport 11:1669-1672.
103. Liu XJ, Salter MW. 2005. Purines and pain mechanisms: recent developments. Curr Opin Investig Drugs 6:65-75.
104. Liu XJ, White TD, Sawynok J. 2000. Potentiation of formalin-evoked adenosine release by an adenosine Idnase inhibitor and an adenosine deaminase inhibitor in the rat hind paw: a microdialysis study. Eur J Pharmacol 408:143-152.
105. Liu XJ, White TD, Sawynok J. 2002. Enhanced release of adenosine in rat hind paw following spinal nerve ligation: involvement of capsaicin-sensitive sensory afferents. Neuroscience 114:379-387.
106. 3 receptors in rat sensory neurons. Neuroreport 9:2245-2250.
107. Lynch ME, Clark AJ, Sawynok J. 2003. Intravenous adenosine alleviates neuropathic pain: a double blind placebo controlled crossover trial using an enriched enrolment design. Pain 103:111-117.
108. McGaraughty S, Chu KL, Wismer CT, Mikusa J, Zhu CZ, Cowart M, Kowaluk EA, Jarvis MF. 2001. Effects of A-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action. J Pharmacol Exp Ther 296:501-509.
109. McGaraughty S, Wismer CT, Zhu CZ, Mikusa J, Honore P, Chu KL, Lee CH, Faltynek CR, Jarvis MF. 2003. Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration. Br J Pharmacol 140:1381-1388.
110. McGaraughty S, Cowart M, Jarvis MF, Berman RF. 2005a. Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr Top Med Chem 5:43-58.
111. 2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain. Br J Pharmacol. 146:180-188.
112. Moriyama T, Iida T, Kobayashi K, Higashi T, Fukuoka T, Tsumura H, Leon C, Suzuki N, Inoue K, Cachet C, Noguchi K, Tominaga M. 2003. Possible involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. J Neurosci 23:6058-6062.
113. Moriyama M, Kitamura A, Ikezaki H, Nakanishi K, Kim C, Sakamoto A, Ogawa R. 2004. Systemic ATP infusion improves spontaneous pain and tactile allodynia, but not tactile hypesthesia, in patients with postherpetic neuralgia. J Anesth 18:177-180.
114. Moser GH, Schrader J, Duessen A. 1989. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 25:c799-c806.
115. Norenberg W, Illes P. 2000. Neuronal P2X receptors: localisation and functional properties. Naunyn Schmiedebergs Arch Pharmacol 362:324-339.
116. 3 purinoceptors in sensory neurons in naïve rats and following neuropathic injury. Pain 80:273-282.
117. Okada M, Nakagawa T, Minami M, Satoh M. 2002. Analgesic effects of intrathecal administration of P2Y nucleotide receptor agonists UTP and UDP in normal and neuropathic pain model rats. J Pharmacol Exp Ther 303:66-73.
118. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F. 1995. The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Neurosci Lett 199:87-90.
119. Pak MA, Haas HL, Decking UKM, Schrader J. 1994. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacology 33:1049-1053.
120. Pan HL, Xu Z, Leung E, Eisenach JC. 2001. Allosteric adenosine modulation to reduce allodynia. Anesthesiology 95:416-420.
121. Park HC, Seong J, An JH, Kim J, Kim UJ, Lee BW. 2005. Alteration of cancer pain-related signals by radiation: proteomic analysis in an animal model with cancer bone invasion. Int J Radiat Oncol Biol Phys 61:1523-1534.
122. Poon A, Sawynok J. 1995. Antinociception by adenosine analogs and an adenosine kinase inhibitor: dependence on formalin concentration. Eur J Pharmacol 286:177-184.
123. Rae MG, Rowan EG, Kennedy C. 1998. Pharmacological properties of P2X3-receptors present in neurons of the rat dorsal root ganglia. Br J Pharmacol 124:176-180.
124. Ralevic V, Burnstock G. 1998. Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492.
125. Regaya I, Pham T, Andreotti N, Sauze N, Carrega L, Martin-Eauclaire MF, Jouirou B, Peragut JC, Vacher H, Rochat H, Devaux C, Sabatier JM, Guieu R. 2004. Small conductance calcium-activated K+ channels, SkCa, but not voltage-gated K+ (Kv) channels, are implicated in the antinociception induced by CGS21680, a A2A adenosine receptor agonist. Life Sci 76:367-377.
126. Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. 1998. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 401:163-186.
127. Sanada M, Yasuda H, Omatsu-Kanbe M, Sango K, Isono T, Matsuura H, Kikkawa R. 2002. Increase in intracellular Ca(2+) and calcitonin gene-related peptide release through metabotropic P2Y receptors in rat dorsal root ganglion neurons. Neuroscience 111:413-422.
128. Sandner-Kiesling A, Li X, Eisenach JC. 2001. Morphine-induced spinal release of adenosine is reduced in neuropathic rats. Anesthesiology 95:1455-1459.
129. Sawynok J. 1999. Purines in pain management. Curr Opin CPNS Invest Drugs 1:27-38.
130. Sawynok J, Liu XJ. 2003. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 69:313-340.
131. Sawynok J, Sweeney MI, White TD. 1986. Classification of adenosine receptors mediating antinociception in the rat spinal cord. Br J Pharmacol 88:923-930.
132. Sawynok J, Zarrindast MR, Reid AR, Doak GJ. 1997. Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine. Eur J Pharmacol 333:1-7.
133. Schaddelee MP, Dejongh J, Collins SD, de Boer AG, Ijzerman AP, Danhof M. 2004. Population pharmacokinetic-pharmacodynamic modelling of the anti-hyperalgesic effect of 5′deoxy-N6-cylopentyladenosine in the mononeuropathic rat. Eur J Pharmacol 504:7-15.
134. Schindler CW, Karcz-Kubicha M, Thorndike EB, Muller CE, Tella SR, Goldberg SR, Ferre S. 2004. Lack of ADO A1 and dopamine D2 receptor-mediated modulation of the cardiovascular effects of the ADO A2A receptor agonist CGS 21680. Eur J Pharmacol 484:269-275.
135. Scholz J, Woolf CJ. 2003. Can we conquer pain? Nat Neurosci 5(Suppl):1062-1067.
136. Schwab JM, Guo L, Schluesener HJ. 2005. Spinal cord injury induces early and persistent lesional P2X4 receptor expression. J Neuroimmunol 163:185-189.
137. Scislo TJ, Kitchen AM, Augustyniak RA, O'Leary DS. 2001. Differential patterns of sympathetic responses to selective stimulation of nucleus tractus solitarius purinergic receptor subtypes. Clin Exp Pharmacol Physiol 28:120-124.
138. Segerdahl M, Sollevi A. 1998. Adenosine and pain relief: A clinical overview. Drug Dev Res 45:151-158.
139. Segerdahl M, Irestedt L, Sollevi A. 1997. Antinociceptive effect of perioperative adenosine in hysterectomy. Acta Anaesthiol Scand 40:792-797.
140. Shryock JC, Belardinelli L. 1997. ADO and ADO receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 79:2-10.
141. Sim JA, Young MT, Sung HY, North RA, Surprenant A. 2004. Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci 24:6307-6314.
142. Sjolund KF, Sollevi A, Segerdahl M, Hansson P, Lundeberg T. 1996. Intrathecal and systemic R-phenylisopropyl-adenosine reduces scratching behaviour in a rat mononeuropathy model. Neuroreport 7:1856-1860.
143. Sjolund KF, Belfrage M, Karlsten R, Segerdahl M, Arner S, Gordh T, Solevi A. 2001. Systemic adenosine infusion reduces the area of tactile allodynia in neuropathic pain following peripheral nerve injury: a multi-centre, placebo-controlled study. Eur J Pain 5:199-207.
144. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA. 2001. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 276:125-132.
145. Soto F, Garcia-Guzman M, Gomez-Hernandez JM, Hollmann M, Karschin C, Stuhmer W. 1996. P2X4: an ATP-activated ionotropic receptor cloned from rat brain. Proc Natl Acad Sci USA 93:3684-3688.
146. 3 receptors. Nature (Lond) 407:1015-1017.
147. Spyer KM, Thomas TA. 2000. Role for ADO in modulating cardiorespiratory responses: a mini-review. Brain Res Bull 53:121-124.
148. Stanfa LC, Kontinen VK, Dickenson AH. 2000. Effects of spinally administered P2X receptor agonists and antagonists on the responses of dorsal horn neurons recorded in normal, carrageenan-inflamed and neuropathic rats. Br J Pharmacol 129:351-359.
149. Stucky CL, Medler KA, Molliver DC. 2004. The P2Y agonist UTP activates cutaneous afferent fibers. Pain 109:36-44.
150. Sukhotinsky I, Ben-Dor E, Raber P, Devor M. 2004. Key role of the dorsal root ganglion in neuropathic tactile hypersensibility. Eur J Pain 8:135-143.
151. Sweitzer S, Martin D, DeLeo JA. 2001. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 103:529-539.
152. Taiwo YO, Levine JD. 1990. Direct cutaneous hyperalgesia induced by adenosine. Neuroscience 38:757-762.
153. 2/3 receptor signaling in capsaicin-insensitive primary afferent neurons. J Neurosci 20:RC90.
154. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K. 2003. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424:778-783.
155. Tsuzuki K, Kondo E, Fukuoka T, Yi D, Tsujino H, Sakagami M, Noguchi K. 2001. Differential regulation of P2X(3) mRNA expression by peripheral nerve injury in intact and injured neurons in the rat sensory ganglia. Pain 91:351-360.
156. Ulugol A, Karadag HC, Tamer M, Firat Z, Aslantas A, Dokmeci I. 2002. Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci Lett 328:129-132.
157. Van Der Graaf PH, Van Schaick EA, Mathot RA, Ijzerman AP, Danhof M. 1997. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-CyclopentylADO analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at ADO A1 receptors. J Pharmacol Exp Ther 283:809-816.
158. Vulchanova L, Arvidsson U, Riedl M, Wang J, Buell G, Surprenant A, North RA, Elde R. 1996. Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. Proc Natl Acad Sci 93:8063-8067.
159. 3 receptor subunits in rat and monkey sensory neurons and their central terminals. Neuropharmacology 36:1229-1242.
160. 3 is expressed by DRG neurons that terminate in inner lamina II. Eur J Neurosci 10:3470-3478.
161. Wang CZ, Namba N, Gonoi T, Inagaki N, Seino S. 1996. Cloning and pharmacological characterization of a fourth P2X receptor subtype widely expressed in brain and peripheral tissues including various endocrine tissues. Biochem Biophys Res Commun 220:196-202.
162. Wang X, Arcuino G, Takano T, Lin J, Peng WG, Wan P, Li P, Xu Q, Liu QS,
163. Watkins LR, Maier SF. 2005. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med 257:139-155.
164. Weick M, Cherkas PS, Hartig W, Pannicke T, Uckermann O, Bringmann A, TaI M, Reichenbach A, Hanani M. 2003. P2 receptors in satellite glial cells in trigeminal ganglia of mice. Neuroscience 120:969-977.
165. Williams M, Jarvis MF. 2000. Purinergic and pyrimidinergic receptors as potential drug targets. Biochem Pharmacol 59:1173-1185.
166. Wismer CT, Faltynek CR, Jarvis MF, McGaraughty S. 2003. Distinct neurochemical mechanisms are activated following administration of different P2X receptor agonists into the hindpaw of a rat. Brain Res 965:187-193.
167. Woolf CJ. 2004. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci 74:2605-2610.
168. Wu WP, Hao JX, Halldner L, Lovdahl C, DeLander GE, Wiesenfeld-Hallin Z, Fredholm BB, Xu XJ. 2005. Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain 113:395-404.
169. Xiang Z, Bo X, Burnstock G. 1998. Localization of ATP-gated P2X receptor immunoreactivity in rat sensory and sympathetic ganglia. Neurosci Lett 256:105-108.
170. Xiao HS, Huang QH, Zhang FX, Bao L, Lu YJ, Guo C, Yang L, Huang WJ, Fu G, Xu SH, Cheng XP, Yan Q, Zhu ZD, Zhang X, Chen Z, Han ZG, Zhang X. 2002. Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. Proc Natl Acad Sci USA 99:8360-8365.
171. Yang L, Zhang FX, Huang F, Lu YJ, Li GD, Bao L, Xiao HS, Zhang X. 2004. Peripheral nerve injury induces trans-synaptic modification of channels, receptors and signal pathways in rat dorsal spinal cord. Eur J Neurosci 19:871-883.
172. Yao ST, Barden JA, Finkelstein DI, Bennett MR, Lawrence AJ. 2000. Comparative study on the distribution patterns of P2X(1)-P2X(6) receptor immunoreactivity in the brainstem of the rat and the common marmoset (Callithrix jacchus): association with catecholamine cell groups. J Comp Neurol 427:485-507.
173. Yoshida K, Nakagawa T, Kaneko S, Akaike A, Satoh M. 2002. Adenosine 5′-triphosphate inhibits slow depolarization induced by repetitive dorsal root stimulation via P2Y purinoceptors in substantia gelatinosa neurons of the adult rat spinal cord slices with the dorsal root attached. Neurosci Lett 320:121-124.
174. Zhang Y, Conklin DR, Li X, Eisenach JC. 2005. Intrathecal morphine reduces allodynia after peripheral nerve injury in rats via activation of a spinal A1 adenosine receptor. Anesthesiology 102:416-420.
175. Zhong Y, Dunn PM, Bardini M, Ford AP, Cockayne DA, Burnstcok, G. 2001. Changes in P2X receptor responses of sensory neurons from P2X3-deficient mice. Eur J Neurosci 14:1784-1792.
176. Zhu CZ, Mikusa J, Chu KL, Cowart M, Kowaluk EA, Jarvis MF, McGaraughty S. 2001. A-134974: a novel adenosine kinase inhibitor, relieves tactile allodynia via spinal sites of action in peripheral nerve injured rats. Brain Res 905:104-110.